Repligen/RGEN

-0.09%
-
1D1W1MYTD1YMAX

About Repligen

Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. The Company's bioprocessing business consists of four main franchises: filtration (including fluid management); chromatography; process analytics, and proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. The Company’s chromatography franchise includes a number of products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. The Company’s TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes.

Ticker

RGEN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Tony Hunt

Employees

1,783

Headquarters

Waltham, United States

Repligen Metrics

BasicAdvanced
US$9.6B
Market cap
681.17
P/E ratio
US$0.25
EPS
1.07
Beta
-
Dividend rate
US$9.6B
1.0672
US$211.13
US$110.45
488K
6.354
5.243
26.079
29.605
202.202
0.55%
0.76%
0.62%
681.166
15.816
4.872
16.106
87.703
-21.9%
-91.43%
20.37%
-12.79%

What the Analysts think about Repligen

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 10 analysts.
19.09% upside
High US$225.00
Low US$170.00
US$171.78
Current price
US$204.58
Average price target

Repligen Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
1.32% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
US$151M
-2.83%
Net income
US$2M
-107.87%
Profit margin
1.32%
-108.09%

Repligen Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 7.18%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
US$0.53
US$0.23
US$0.33
US$0.28
-
Expected
US$0.48
US$0.17
US$0.33
US$0.30
US$0.33
Surprise
11.52%
38.68%
1.37%
-7.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Repligen stock?

Repligen (RGEN) has a market cap of $9.6B as of May 20, 2024.

What is the P/E ratio for Repligen stock?

The price to earnings (P/E) ratio for Repligen (RGEN) stock is 681.17 as of May 20, 2024.

Does Repligen stock pay dividends?

No, Repligen (RGEN) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Repligen dividend payment date?

Repligen (RGEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Repligen?

Repligen (RGEN) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Repligen stock price target?

The target price for Repligen (RGEN) stock is $204.58, which is 19.09% above the current price of $171.78. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Repligen stock

Buy or sell Repligen stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing